Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT07202260

Pragmatic Analysis of Complex Radiotherapy Cases In Cancer of the Lung

This study focuses on improving care for people with lung cancer who face unusual or complex treatment situations.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Lung Cancer (NSCLC) Bronchial Neoplasms Carcinoma, Bronchogenic Carcinoma, Non-Small-Cell Lung Lung Cancer (SCLC) Lung Diseases Lung Diseases, Interstitial Lung Neoplasms Neoplasms Neoplasms by Site Respiratory Tract Diseases Respiratory Tract Neoplasms Thoracic Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

The Christie NHS Foundation Trust

Withington, Greater Manchester, M20 1BX, United Kingdom

About this study

By studying detailed patient data, researchers aim to find the best ways to treat these patients while reducing short- and long-term side effects. The findings will help refine radiotherapy treatments, ensuring they are as safe and effective as possible. Additionally, the results will provide doctors with better information to help patients understand the potential risks and benefits of their treatment options.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Complex patients with lung cancer undergoing radiotherapy in one of the following groups;

  • Rare histology
  • Disease invading vascular structures
  • Co-existing interstitial lung disease (ILD)
  • Radical re-irradiation
  • Oligopersistent/oligoprogressive disease on immunotherapy or targeted therapies.

Exclusion criteria

  • Include patients with stage IV disease who are receiving non-curative intent radiotherapy
  • There are no exclusion criteria relating to upper age limit or comorbidities.

Treatment and study plan

Primary outcomes

  1. Acute and late toxicity

    Time frame: 2 years

    • Acute (<90 days post radiotherapy) and late (> 90 days post radiotherapy) toxicity according to common terminology criteria for adverse events (CTCAE) V5.

Other outcomes

  1. Patient reported quality of life

    Time frame: 2 years

    • Patient reported quality of life (QOL) information from electronic patient reported outcome measure (ePROM) questionnaires.

  2. Survival

    Time frame: 2 years

    • Progression-free survival and overall survival.

Sponsors and collaborators

Lead sponsor

The Christie NHS Foundation Trust

Other

Registry information

Official study title

Pragmatic Analysis of Complex Radiotherapy Cases In Cancer of the Lung (The PRACTICAL Study)

Acronym: PRACTICAL

Important dates

Study start
2025
Primary completion
2028
Study completion
2028
First posted
Oct 1, 2025
Registry last updated
Oct 1, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.